Rasburicase
Form: Injection
Strength: 1.5 mg/1.5 mL (1.5 mg vial)
Reference Brands: Elitek® (US & EU)
Category: Oncology Cancer Care
Rasburicase is an enzyme therapy used for the prevention and treatment of tumor lysis syndrome (TLS) in patients with hematologic malignancies, such as leukemia and lymphoma. It is a recombinant urate oxidase that helps lower elevated uric acid levels, which can occur after chemotherapy. Available under the brand Elitek®, Rasburicase is marketed in 1.5 mg vials for injection in the US and EU. Manufactured under GMP-compliant standards, it is a vital product for oncology B2B pharma distributors and is supplied for use in hospitals and treatment centers globally.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details Get Enquiry
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details Get Enquiry
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details Get Enquiry
Ifosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details Get Enquiry